Diagnostic Imaging Pathways Logo

  • Pathways
  • Normal Anatomy
  • Medical Images
  • Radiation Module
  • Radiation Quiz
  • Menu
  • Search

Hypertension

Population Covered By The Guidance

This pathway provides guidance on the investigation of adult patients with hypertension who need investigation for causes of secondary hypertension.

Lead Researcher: Sian Chin

Experts & Contributors: Aron Chakera, Ravinder Dhillon

Editorial Panel: Core membership
Link to Editorial Panel

Date reviewed: July 2018

Date Published: March 2019

Image 1a, 1b and 1c (Digital Subtraction Angiography): Pre- and post-stent images of bilateral renal artery stenosis

Bilateral Renal Artery Stenosis

Image 1a, 1b and 1c (Digital Subtraction Angiography): Pre- and post-stent images of bilateral renal artery stenosis

Bilateral Renal Artery Stenosis

Image 1a, 1b and 1c (Digital Subtraction Angiography): Pre- and post-stent images of bilateral renal artery stenosis

Bilateral Renal Artery Stenosis

Image 2a and 2b (Magnetic Resonance Imaging): There is a 13mm right sided pituitary adenoma (arrows) causing deviation of the stalk to the left. Slight suprasellar extension is noted without impingement of the chiasm or optic nerves.

Cushing's Disease

Image 2a and 2b (Magnetic Resonance Imaging): There is a 13mm right sided pituitary adenoma (arrows) causing deviation of the stalk to the left. Slight suprasellar extension is noted without impingement of the chiasm or optic nerves.

Cushing's Disease

Image 3 (Computed Tomography): Round low attenuation lesion at upper pole of left kidney consistent with phaeochromocytoma (arrow).

Phaeochromocytoma

Image 4a (I123-MIBG) and 4b (Computed Tomography): High grade focus of uptake identified at the left side of the upper abdomen posteriorly (arrow). CT demonstrates a cystic phaeochromocytoma (arrow).

Phaeochromocytoma

Image 4a (I123-MIBG) and 4b (Computed Tomography): High grade focus of uptake identified at the left side of the upper abdomen posteriorly (arrow). CT demonstrates a cystic phaeochromocytoma (arrow).

Phaeochromocytoma

Image 5a (I123-MIBG) and 5b (SPECT): Low grade focus of uptake identified at the left side of the upper abdomen posteriorly (arrow). SPECT imaging confirms the focus of uptake at the upper pole of the left kidney, in the region of the left adrenal gland (arrow).

Phaeochromocytoma

Image 5a (I123-MIBG) and 5b (SPECT): Low grade focus of uptake identified at the left side of the upper abdomen posteriorly (arrow). SPECT imaging confirms the focus of uptake at the upper pole of the left kidney, in the region of the left adrenal gland (arrow).

Phaeochromocytoma

Image 6 (H&E, x10): Histological section of a phaechromocytoma showing a nested architecture (zellballen pattern) separated by thin fibrous septae. The cells demonstrate finely granular amphophilic cytoplasm.

Phaeochromocytoma

  • Secondary hypertension is uncommon and blanket screening for secondary hypertension is not routinely recommended
  • If clinic blood pressure is ≥140/90mmHg, or hypertension is suspected, ambulatory and/or home monitoring should be offered to confirm the blood pressure level
  • In cases of apparent resistant hypertension, it is important to specifically ask about medication compliance
  • The initial assessment of patients with a new diagnosis of hypertension should include a thorough history and examination to elicit features that may suggest specific causes of secondary hypertension, as well as evidence of target organ damage. Basic screening tests include: urine dipstick, urinary albumin/creatinine ratio, fasting blood glucose, fasting lipid profile, serum urea, electrolytes, creatinine with eGFR, haemoglobin, fundoscopy and ECG (to assess for left ventricular hypertrophy)
  • There are many causes of secondary hypertension and investigations should be targeted depending on the differential diagnosis

  1. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-54. (Review article).View the reference
  2. Ng FL, Lobo MD. Investigation and management of adult hypertension. Heart. 2018. (Review article).View the reference
  3. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults - 2016. Melbourne: National Heart Foundation of Australia; 2016. (Guideline). View the reference
  4. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324. (Guideline). View the reference 
  5. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557-76. (Guideline). View the reference
  6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. (Guideline). View the reference

Pathway User Guide

Yellow Boxes Denotes extra information. Some contain single or multiple white sub-boxes, click a white box to reveal detailed information in a pop-up.

White Boxes: Denotes standard pathway steps. (If inside a yellow box, they open a specific pop-up).

Zoom & Pan Controls: Use + / − or the slider to zoom. Reset returns to default. Tick Panning to drag the diagram when zoomed.

Blue “View Full Screen” Button: Opens the whole diagram in a large, full-screen pop-up window. Use Close to exit.

The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.

SYMBOL RRL EFFECTIVE DOSE RANGE
No radiation None 0
Minimal radiation Minimal < 1 millisieverts
Low radiation Low 1-5 mSv
Medium radiation Medium 5-10 mSv
High radiation High >10 mSv

Disclaimer

Status Of Recommendations Each pathway is designed to assist clinicians in situations when faced with a large array of possible diagnostic tests and examinations. However, it is recognised that diagnostic practice may differ from a particular pathway depending on local availability of equipment and expertise, as well as the experience of individual clinicians. Therefore each pathway is neither a rigid set of rules, nor a substitute for clinical assessment, and individual patient circumstances should always be considered.

Report an Issue

Spotted an error or outdated info? Click to tell us.

Date reviewed: July 2018 Please note that this pathway is subject to review and revisionFurther investigation may involve imaging if certain underlying causes are suspected. Consider specialist referralCharacteristics suggestive of secondary hypertension:• Early onset <30 yrs• Resistant hypertension (>140/90mmHg despite three antihypertensives including a diuretic)• Severe hypertension (>180/110mmHg) • Hypertensive emergency• Exacerbation of previously controlled hypertension• Clinical features specific to certain secondary causes, including biochemical abnormalities or renal dysfunctionADULT WITH NEW ONSET OR UNCONTROLLED HYPERTENSIONGo to the Renovascular Hypertension PathwayGo to the Phaeochromocytoma PathwayGo to the Cushing's Syndrome PathwayGo to the Hyperthyroidism PathwayGo to the Hyperaldosteronism Pathway

Screening for Secondary Hypertension

Screening for Secondary Hypertension

Secondary hypertension is rare and blanket screening is not recommended but certain features may prompt further investigation

  • Only 5-10% of patients with hypertension have secondary hypertension
  • Blanket screening for secondary hypertension is not routinely recommended
  • If clinic blood pressure is ≥140/90mmHg, or hypertension is suspected, ambulatory and/or home monitoring should be offered to confirm the blood pressure level
  • The initial assessment of patients with a new diagnosis of hypertension should include a thorough history and examination to elicit features that may suggest specific causes of secondary hypertension, as well as evidence of target organ damage. Basic screening tests include: urine dipstick, urinary albumin/creatinine ratio, fasting blood glucose, fasting lipid profile, serum urea, electrolytes, creatinine with eGFR, haemoglobin, fundoscopy and ECG (to assess for left ventricular hypertrophy)
  • In cases of apparent resistant hypertension, it is important to specifically ask about medication compliance
  • Screening for specific form(s) of secondary hypertension is recommended in certain circumstances:

Characteristics Suggestive of Secondary Hypertension

  • Early onset 1,4,5
  • Resistant hypertension – (>140/90mmHg despite three antihypertensive agents including a diuretic)
  • Severe hypertension >180/110mmHg or hypertensive emergencies
  • Exacerbation of previously controlled hypertension
  • Clinical features specific to certain secondary causes – including biochemical abnormalities (such as excessive hyperkalaemia ), or renal dysfunction

There are many causes of secondary hypertension and investigations should be targeted depending on the differential diagnosis

  • Causes of secondary hypertension include:
    • Renal parenchymal disease
    • Renovascular disease, including renal artery stenosis due to fibromuscular dysplasia
    • Primary hyperaldosteronism
    • Obstructive sleep apnoea (although there is mixed evidence on the benefit of treatment)
    • Drug or alcohol induced
  • Rarer causes:
    • Phaeochromocytoma
    • Cushing’s syndrome
    • Hypo/hyperthyroidism
    • Aortic coarctation
    • Primary hyperparathyroidism
    • Congenital adrenal hyperplasia
    • Other mineralocorticoid excess syndromes
    • Acromegaly

Renovascular Hypertension

Renovascular Hypertension

May be suspected in resistant hypertension. Can be caused by atherosclerotic disease, or by fibromuscular dysplasia especially in younger female patients without other risk factors

Hypertension (renovascular cause)

Phaeochromocytoma

Phaeochromocytoma

May have resistant, labile or paroxysmal hypertension including hypertensive crises. May have other symptoms of catecholamine excess. Consider in patients with predisposition to hereditary causes

Phaeochromocytoma (suspected)

Hyperaldosteronism

Hyperaldosteronism

Suspect if unexplained hypokalaemia is present

Hyperaldosteronism (primary suspected)

Cushing’s Syndrome

Cushing’s Syndrome

Suspect if other clinical features of Cushing’s Syndrome are present such as weight gain, hyperglycaemia, “moon” face and central obesity

Cushing's syndrome

Hyperthyroidism

Hyperthyroidism

Can be suspected if other clinical features are consistent with hyperthyroidism such as palpitations, weight loss, diarrhea, tremor or ophthalmopathy

Hyperthyroidism

  • Acute Abdomen
  • Breast
  • Cancer Staging
  • Cardiovascular
  • Ear, Nose & Throat
  • Endocrine
  • Gastrointestinal
  • Kidney and Urinary Tract
  • Liver and Biliary
  • Musculoskeletal Non-Trauma
  • Neurological
  • Obstetric & Gynaecological
  • Paediatric
  • Pancreas
  • Respiratory
  • Trauma
    • Trauma - Musculoskeletal
    • Trauma - Head
    • Trauma - Visceral
    • Trauma - Paediatric
  • Cardiovascular

    • Cardiovascular
      • Abdominal aortic aneurysm (Repair follow-up)
      • Abdominal Aortic Aneurysm (Screening and Investigation)
      • Angina (Stable, Suspected)
      • Aortic Dissection (Spontaneous, Suspected)
      • Coronary Syndrome (Acute, Suspected)
      • Deep Venous Thrombosis (Arm, Suspected)
      • Deep Venous Thrombosis (Leg, Suspected)
      • Hypertension
      • Hypertension (Suspected Renovascular Cause)
      • Leg ischaemia (acute)
      • Mesenteric Ischaemia (Chronic, Suspected)
      • Peripheral Arterial Disease (Suspected)
      • Peripheral Arterial Stent (Follow-Up)
    • Respiratory
      • Chest X-Ray (Pre-Operative Indications)

    Diagnostic Imaging Pathways

    The DIP pathways are a step-by-step guides to help clinicians choose the most appropriate imaging for each clinical scenario 

    “Trusted by clinicians worldwide since 2007, Diagnostic Imaging Pathways provides clear, evidence-based imaging guidelines. Our pathways support better decision-making and help improve healthcare outcomes—especially in emerging nations. 

    DIP functions and thrives wholeheartedly under the pillars of diversity, inclusivity and respect for all."

    • Pathways
    • Normal Anatomy
    • Medical Images
    • Radiation Module
    • Radiation Quiz
    • Information for Consumers
    • Governance
    • About Imaging
    • Production
    • Search
    • Login
    • Get in Touch
    © Diagnostic Imaging Pathways (DIP) 2025
    Code of Conduct    Terms and Conditions of Use
    General Site Navigation

    Information For Consumers

    • General Information About Diagnostic Imaging
      • Colorectal (Bowel) Cancer Screening
      • Colorectal (Bowel) Cancer Screening (Australia)
      • Consent to Procedure or Treatment
      • Radiation Risks of X-rays and Scans
    • Imaging Pathways
      • Ankle Injury (Suspected)
      • Bowel Cancer (Staging)
      • Deep Venous Thrombosis ( Leg, Suspected)
      • Deep Venous Thrombosis (Arm, Suspected)
      • Headache (Constant or Repeated)
      • Hip Fracture (Suspected)
      • Hypertension
      • Low Back Pain (Acute)
      • Lung Cancer (Staging)
      • Neck Pain (Non-Traumatic)
      • Renal Colic
      • Respiratory Illness (Acute)
      • Scaphoid Fracture (Suspected)
      • Shoulder (Pain or Instability)
      • Sinusitis (Acute)
      • Sinusitis (Chronic)
      • Stress Fracture (Suspected)
    • Imaging Procedures
      • Angiography (Angiogram)
      • Arthrogram
      • Bone Scan
      • Computed Tomography (CT)
      • Computed Tomography (CT) Angiography
      • Inferior Vena Cava (IVC) Filters
      • Intravenous Pyelogram (IVP)
      • Magnetic Resonance Angiography (MRA)
      • Magnetic Resonance Imaging (MRI)
      • Myelogram
      • Orthopantomogram (OPG)
      • Percutaneous Transthoracic Fine Needle Aspiration (FNA) or Biopsy
      • Positron Emission Tomography (PET)
      • Renal Artery Angioplasty and Stent
      • Renal Scan
      • Ultrasound
      • Ultrasound (Doppler)
      • Ultrasound (Endoscopic Rectal)
      • Venography (Venogram)
      • X-ray (Chest)
      • X-ray (Plain Radiograph)

    Governance

    • History
      • 1990s to 2012
      • 2012 to 2016
      • 2016 to 11 April 2022
      • From 12 April 2022
      • Introduction
      • List of acronyms used on this site
    • Organisation
      • 2003 - 2012
      • 2013 - 2016
      • 2017 - 11 April 2022
      • Post 12 April 2022
    • Personnel
      • Clinical Advisors
      • Contractors
      • Contributors
      • Editor
      • Editorial Panel - Post 2022
      • Editorial Panel - Pre 2022
      • Executive Sponsor
      • Information Technologist
      • Manager
      • Other Personnel
      • Project Officers
      • Quality Coordinator
      • Research Registrar
      • Responsibilites
      • Steering Committee
      • Steering Committee
    • Responsibilities, Achievements
      • Accreditation and Endorsement
      • Clinical Advisors
      • Editor
      • Editorial Panel
      • Executive Sponsor
      • Information Technologist
      • Manager
      • Other Personnel
      • Pathway Creation, Review and Revision
      • Quality Coordinator
      • Research Registrar
      • Steering Committee

    About Imaging

    • About Imaging
      • Bleeding Risk and Assessment
      • General Principles in Requesting and Providing Imaging Investigations
      • Imaging During Pregnancy and Lactation
      • Ionising Radiation in Diagnostic Imaging
      • Ionising Radiation in Paediatric Imaging
    • Common Procedures
      • Computed Tomography
      • Gastrointestinal Contrast Examinations
      • High Resolution Computed Tomography
      • Magnetic Resonance Imaging
      • Nuclear Medicine
      • Positron Emission Tomography
      • Ultrasound
    • Contrast Agents
      • Gadolinium Contrast for MRI scans
      • Iodinated Contrast for CT scans
      • Ultrasound Contrast Media

    Production

    • Editorial Independence
      • Disclosure of Conflict of Interest
      • Funding Policy & Sources
      • Management of Conflict of Interest
    • Processes for Creating and Managing Content
      • Creation of a New Pathway
      • Creation of New Information for Consumers
      • Review and Revision of a Pathway
      • Review and Revision of Information for Consumers
    • Production
      • Initial Engagement with Consumers
      • Principles for Creating and Managing Content